Table 3.
Changes between baseline and endpoint in metabolic and laboratory markers in the two groups
| Variables | Dapagliflozin (n = 14) | DPP-4 inhibitors (n = 15) | Change difference between groups p value |
|---|---|---|---|
| Mean change (95% CI) | Mean change (95% CI) | ||
| HbA1c (%) | 0.48 (0.17 to 0.79)†† | 0.24 (−0.13 to 0.61) | 0.30 |
| Glycated albumin (%)a | 1.04 (−0.14 to 2.21) | 0.55 (−0.91 to 2.01) | 0.58 |
| Body mass index (kg m−2) | −0.90 (−1.42 to −0.39)†† | 0.12 (−0.12 to 0.36) | 0.001 |
| Systolic BP (mmHg)b | −2.8 (−11.5 to 5.8) | 4.5 (−5.7 to 14.6) | 0.25 |
| Diastolic BP (mmHg)b | 4.1 (−3.2 to 11.4) | 2.0 (−2.9 to 6.9) | 0.61 |
| Hemoglobin (g dL−1)a | 0.44 (0.05 to 0.83)† | 0.01 (−0.43 to 0.47) | 0.13 |
| Hematocrit (%)a | 1.61 (0.46 to 2.77)† | −0.23 (−1.61 to 1.15) | 0.04 |
| ALT (U L−1) | −2.0 (−26.0 to 6.0) | 1.0 (−4.0 to 11.0) | 0.03‡ |
| Uric acid (mg dL−1) | −0.54 (−1.10 to 0.03) | 0 (−0.37 to 0.32) | 0.11 |
| Estimated GFR [mL min−1 (1.73 m2)−1] | 1.3 (−11.7 to 9.0) | 3.0 (−4.9 to 13.6) | 0.42‡ |
| Log UACRa | −0.16 (−0.32 to 0)† | 0.04 (−0.10 to 0.17) | 0.05 |
Values are mean ± SD or median (25–75% CI). P values: mean changes from baseline to the end of the study between the Dapagliflozin group and the DPP-4 inhibitors group. † P < 0.05 and †† P < 0.01 between baseline and the end of the study, (paired t test or Wilcoxon signed-rank test). ‡ Mann–Whitney U test
BP blood pressure, ALT alanine-aminotransferase, LDL low-density lipoprotein, HDL high-density lipoprotein, GFR glomerular filtration rate, UACR urine albumin to creatinine ratio
aData from 28 patients
bData from 27 patients